Presentations—prIME Masterclass in Neuroendocrine Tumors - prIME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations—prIME Masterclass in Neuroendocrine Tumors

Downloadable Slides From a prIME Oncology Meeting

Not a member of My prIME? Join now for instant access.

Improve your understanding of neuroendocrine tumors (NETs) with insights from the experts on epidemiology, clinical characteristics, natural history, pathophysiology, and current and emerging treatment strategies for patients with functioning and nonfunctioning NETs.

Release Date

Release Date

Nov 15, 2017

Expiration Date

Nov 15, 2018

Downloadable Slides

Downloadable Slides

Featured Expert

  • Ulrich-Frank Pape, MD, Charité University Hospital, Berlin, Germany

Featured Topic

Epidemiology and prognosis of NETs

Featured Expert

  • Jean-Yves Scoazec, MD, PhD, Gustave Roussy, Villejuif, France

Featured Topic

Pathology of NETs in 2017

Featured Expert

  • Marnix Lam, MD, PhD, University Medical Center Utrecht, Utrecht, the Netherlands

Featured Topic

Locoregional treatments

Featured Expert

  • Jaume Capdevila, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

Featured Topic

Exploring treatment options for patients with metastatic GEP NETs

Featured Expert

  • Marianne Pavel, MD, University Hospital Erlangen, Erlangen, Germany

Featured Topic

Pulmonary NETs: Similarities and differences in management of GEP NETs

Featured Expert

  • Matthias Weber, MD, Johannes Gutenberg University Mainz, Mainz, Germany

Featured Topic

Safe delivery of targeted treatments for NETs

Featured Expert

  • Philippe Ruszniewski, MD, University of Paris VII, Beaujon Hospital, Paris, France

Featured Topic

Medical complications of NETs

Featured Expert

  • Rolf Kiessling, MD, PhD, Karolinska Institutet, Stockholm, Sweden

Featured Topic

Immunotherapy for cancer: Implications for future NET management

Featured Expert

  • Richard Baum, MD, PhD, Zentralklinik Bad Berka, Bad Berka, Germany

Featured Topic

Peptide receptor radionuclide radiotherapy—How, why, and when?

Featured Expert

  • Prakash Manoharan, MBChB, MRCP, FRCR 
, The Christie Neuroendocrine Centre of Excellence, Manchester, United Kingdom

Featured Topic

Imaging of NETs: Toward a one-stop shop

Featured Expert

  • Teodora Kolarova, International Neuroendocrine Cancer Alliance, Sofia, Bulgaria

Featured Topic

Meaningful patient advocacy

Featured Expert

  • Vincenzo Corbo, PhD, University and Hospital Trust of Verona, Verona, Italy

Featured Topic

Emerging developments in NETs: Biology and molecular pathology

Featured Expert

  • Maxime Ronot, MD, PhD, Beaujon University Hospital, Clichy, France

Featured Topic

Emerging developments in NETs: Imaging

Featured Expert

  • Dermot O’Toole, MD, FRCPI, St Vincent’s University Hospital, St James's Hospital
    Trinity College Dublin, Dublin, Ireland

Featured Topic

Emerging developments in NETs: Therapeutic developments

Featured Experts

  • Dermot O’Toole, MD, FRCPI, St Vincent’s University Hospital, St James's Hospital
    Trinity College Dublin, Dublin, Ireland
  • Philippe Ruszniewski, MD, University of Paris VII, Beaujon Hospital, Paris, France

Featured Topic

prIME Points™

This educational activity is designed for European medical oncologists, endocrinologists, gastroenterologists, nuclear medicine specialists, and other healthcare providers involved in the management of patients with NETs.

After successful completion of this educational activity, participants should be able to:

  • Describe the epidemiology, clinical characteristics, natural history, and pathophysiology of NETs
  • Describe the various treatment pathways for functioning and nonfunctioning NETs
  • Evaluate the various therapeutic options available for first and subsequent lines of treatment
  • Identify the potential for novel therapeutic strategies in the treatment of NETs
  • Define the role of modern functional imaging technologies in the evaluation of NETs

This educational activity is supported by Ipsen.

ENDURING MATERIAL FROM A CERTIFIED ACTIVITY

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Baum has disclosed that he has received grants or research support from Advanced Accelerator Applications (AAA) and ITG Isotope Technologies Garching GmbH. He has also received honoraria or consultation fees from AAA, Ipsen Medical, and ITG Isotope Technologies Garching GmbH, and he is stock shareholder of AAA. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Capdevila has disclosed that he has received grants or research support from AAA, Ipsen, Novartis, and Pfizer. He has also participated in company sponsored speaker’s bureaus for AAA, Ipsen, Novartis and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Corbo has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr De Herder has disclosed that he has received grants or research support from Ipsen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kiessling has disclosed that he has received honoraria or consultation fees from Bristol-Myers Squibb and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Teodora Kolarova has disclosed that she has received grants or research support from AAA (for the lliance [INCA]), Ipsen, Novartis, and Pfizer. She has also received honoraria or consultation fees from and participated in a company sponsored speaker’s bureau for Novartis. She has agreed to disclose any  unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lam has disclosed that he has received honoraria or consultation fees from BTG, Mirada, and Sirtex. The department of Radiology and Nuclear Medicine of the UMC Utrecht receives royalties from Quirem Medical. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Manoharan has disclosed that he has received honoraria or consultation fees from AAA, Siemens, Sirtex, and Therusphere.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr O’Toole has disclosed that he has received grants or research support from Ipsen and Novartis. He has also received honorarium or consultation fees from Ipsen and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pape has disclosed that he has received grants or research support from Ipsen and Novartis. He has also received honoraria or consultation fees from Ipsen and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pascher has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pavel has disclosed that her institution has received grants or research support from Ipsen and Novartis. She has also received honoraria or consultation fees from Ipsen, Lexicon, Novartis, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ronot has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ruszniewski has disclosed that he has received grants or research support from Ipsen and Novartis. He has also received honoraria or consultation fees from AAA, Ipsen, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Scoazec has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Weber has disclosed that he has received grants or research support from, honoraria or consultation fees from, and participated in a speaker’s bureau for Ipsen and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – research support received by
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.